Physician profile
Andrew Albert
NPI 1659413656
$19,966.79
in general payments reported to CMS, 2019-2025
18 companies · $5,031 in 2025
The $5,031 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2021: $160 · 2022: $154 · 2023: $3,440 · 2024: $11K · 2025: $5,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,045 · Consulting Fee: $4,596 · Honoraria: $3,706 · Travel and Lodging: $1,467 · Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,045.00 |
| Consulting Fee | $4,596.00 |
| Honoraria | $3,706.00 |
| Travel and Lodging | $1,467.44 |
| Food and Beverage | $708.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $13,212.81 | 2024-2025 | Zymfentra |
| Takeda Pharmaceuticals U.S.A., INC. | $3,398.88 | 2023 | Entyvio |
| Exact Sciences Corporation | $2,500.00 | 2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $160.52 | 2021-2024 | Stelara |
| Abbvie INC. | $155.00 | 2021-2025 | Rinvoq |
| Madrigal Pharmaceuticals | $143.75 | 2024-2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $124.64 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.62 | 2019 | |
| Ardelyx, INC. | $33.65 | 2024 | Ibsrela |
| Cook Medical LLC | $33.33 | 2019 | |
| Covidien Lp | $30.77 | 2019 | |
| Pfizer INC. | $28.99 | 2024 | |
| Qol Medical, LLC | $26.75 | 2024 | Sucraid |
| Fresenius Kabi USA, LLC | $23.66 | 2023 | Idacio |
| Lilly USA, LLC | $22.09 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.50 | 2019 | |
| Allergan, INC. | $12.34 | 2019 | |
| Organon LLC | $5.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.